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Abstract 
Background: Chronic spontaneous urticaria (CSU) poses problems with respect to high prevalence, reduced quality 
of life, lack of long term efficacy, and expense of current treatments for severe intractable symptoms. There have been 
many reports suggesting ‘stress’ factors may be implicated, but there are no studies that explore the efficacy of treat-
ments including a psychological perspective. A whole person treatment approach (WPTA), which addresses psycho-
logical factors has been used, with effect, for 6 years in the Auckland City Hospital Immunology Department.
Findings: In a pilot study to demonstrate feasibility of recruitment and treatment of CSU patients in a time-limited, 
whole person treatment approach, within a conventional immunology department, four patients (three CSU and 
one idiopathic angioedema) were recruited into a brief WPTA course based in non-dualistic concepts of mind and 
body connectedness, and utilising psychotherapy-derived listening skills for up to 10 h long sessions, once per week. 
Treatment efficacy rating, using Urticaria Activity Score and the Urticaria Severity Score, and reduction of drug usage, 
showed patients experienced long term resolution of urticaria and cessation of hospitalisation for angioedema and 
came off regular antihistamine medication.
Conclusions: A clinician treating chronic spontaneous urticaria in an Immunology department, using a whole 
person treatment paradigm, can safely explore unique meanings and emotional states, in a process acceptable to 
patients, resulting in a significant clinical benefit for symptoms. A much larger study comparing the outcome of WPTA 
versus standard treatment alone is warranted.
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Background
Chronic spontaneous urticaria (CSU) will affect 1–5  % 
of the population during their lifetime [1]. This condi-
tion constitutes approximately 25  % of the referrals to 
the Department of Immunology at Auckland City Hos-
pital. International drug treatment guidelines for CSU 
management target histamine receptors and immune 
mechanisms, but CSU is frequently unresponsive to anti-
histamine and immunosuppressive medications [2], and 
the impact of CSU on quality of life is often underesti-
mated by physicians [3]. New biologic drugs targeting IgE 
antibodies such as omalizumab can induce but not main-
tain long-term remission [4]. The medical literature sug-
gests a role for stress [5–7] and emotional factors in CSU 
[8]. Since 2008, in our department, many CSU patients 
have been treated with an individualised, non-dualistic 
whole person treatment approach (WPTA) (see Addi-
tional file  1: Appendix 1) [9–13]. This small pilot study 
was conducted to demonstrate grounds, acceptability, 
feasibility, and potential usefulness of a whole person 
approach, and to develop guidelines for a larger formal 
outcome study.
Methods
The WPTA [9, 11] actively addresses the impact on the 
body of all kinds of life events and relational dynamics. 
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The WPTA clinician sees the patient’s wheals or angi-
oedema as potentially meaningful in the context of these 
events, and focuses upon flare-ups of CSU symptoms to 
access the links between mind and body. The patient and 
the clinician collaborate in making these connections 
with the expressed intention of reducing the symptoms 
over time. Participants were interviewed by KL, MS and 
JG throughout the study both by email and using face 
to face interviews, and the detailed analytic findings 
using qualitative methodologies of Grounded Theory 
and Interpretive Phenomenological Analysis are to be 
reported elsewhere.
Clinical data such as age, gender, medications, and 
duration of symptoms were obtained from the hospital 
notes. Two disease activity measures for each patient 
were recorded before the study at the time of consenting, 
and after the WPTA was completed:
1. The Urticaria Activity Score (UAS) [14]. Patients 
were asked to score once daily for 7  days both the 
number of wheals and severity of pruritus, in a range 
0–3, with a combined maximum possible score of 42. 
Forms were then returned to the department by post 
or self-delivered.
2. The Urticaria Severity Score (USS) [15]. This is based 
on 12 questions ‘designed to measure distinct aspects 
of QOL impairment, the degree and duration of 
pruritus and/or swelling, distribution of body area 
with hives and/or itch, and amount of medication 
required to control symptoms’. It assesses severity of 
urticaria symptoms, and treatment required, over the 
previous 7 days, with a maximum score of 93 and a 
minimum of 0.
The study proposal was reviewed by the New Zealand 
Northern Y regional Ethics committee (NTY/10/05/047). 
In an open recruitment, patients were invited to take 
part by senior staff responsible for their care within the 
Immunology Department, a tertiary specialist service. 
They were given a one page patient information sheet 
which described the WPTA, and then contacted by the 
lead researcher (KL) and again invited to take part.
Recruitment
Fifteen patients were referred and screened for entry. 
The study comprised the first four patients (hereaf-
ter numbered 1–4) who were both eligible and accept-
ing of the research process. The study group comprised 
three females and one male, mean age 55.2. There were 
five more people eligible and willing in principle, but 
who could not enter because the prospect of 10  weekly 
visits to the hospital interfered unacceptably with work. 
Four patients rejected the WPTA as described to them 
by KL. The first four patients who agreed to participate 
became the subjects for the study. All four were naive to 
the WPTA at recruitment, and were told that the study 
involved an approach that ‘treats the mind and the body 
as one entity rather than as two unconnected or sepa-
rate things’ and would involve up to ten sessions lasting 
30–60  min, with a clinician who is both an immunolo-
gist and a trained psychotherapist (Patient Information 
Sheet).
Three patients (all with typical CSU of unknown aetiol-
ogy) underwent ten sessions of WPTA with BB (immu-
nologist/psychotherapist). One person (patient 4) had 
seven sessions. Patient 4 was originally accepted on the 
referral basis that he had CSU with severe angioedema, 
requiring repeated hospitalisations with life threaten-
ing angioedema, but turned out to have no symptoms of 
wheals or hives.
Findings
The three CSU patients had persistent very frequent 
urticarial symptoms and were regarded by referrers as 
not responding to standard treatment. They were tak-
ing maximal doses of antihistamines currently available 
in New Zealand; cetirizine or loratadine up to 40  mg 
daily, with additional fexofenadine up to 180  mg daily, 
without relief of symptoms. No patient had ever been 
trialled on disease-modifying agents. The fourth patient 
had declined antihistamine medications as they were 
ineffective in preventing recurrent angioedema. Table  1 
has patients’ ages, disease duration, and scores before 
and after the WPTA intervention. Three of four had 
improved UAS [16] and USS scores [17], with almost no 
disease activity at the end of the study, and reduced drug 
use to less than monthly antihistamines only, an effect 
which was sustained in all three at telephone follow up 
at 2  years post-WPTA. The fourth patient experienced 
reductions of serious hospitalisation for angioedema 
involving intubation and stays on the intensive care unit. 
Most patients recruited saw the WPTA as a psychother-
apy/counselling-like intervention. Patients did experience 
coincident flares of urticaria and emotion, of which they 
became increasingly aware during the therapeutic ses-
sions, or shortly afterwards. Symptom increases were 
treated as meaningful and were used to good effect by the 
clinician to make links between experience and urticaria, 
affect and emotion, and formed part of the therapeutic 
intervention.
In retrospect, it was evident that during pre-referral 
management all four study subjects had had ‘stress’ iden-
tified as a trigger to their symptoms, and that this along 
with difficulty in biomedical management had in part 
prompted their referral to the study. Patient 4 did not 
score highly in the CSU-focussed questionnaires because 
Page 3 of 4Lindsay et al. Clin Transl Allergy  (2015) 5:40 
he suffered predominantly from intermittent (but severe 
life-threatening) angioedema as part of his CSU.
Discussion
The standard biomedical approach is dualistic, that is, it 
more or less assumes that mind and body are separate, 
and does not value or emphasise the importance of emo-
tional factors to the physical manifestations of disease, 
and therefore they are rarely attended to. This pattern 
is reflected in the general approach to CSU, though one 
other centre has utilised both a biomedical and psycho-
logical approach [18].
This proof-of-concept study recruited four patients 
prospectively to a 10  week, non-dualistic, psychologi-
cally-oriented, mind AND body intervention (WPTA), 
with the clinician being an immunologist who is also a 
psychotherapist. It is the first study to show an interven-
tion which results in a resolution of CSU in a group of 
treatment-resistant patients. Whilst it supports our expe-
rience of using the WPTA routinely and successfully in 
the Clinical Immunology Department at Auckland City 
Hospital, it primarily establishes a precedent for a larger 
comparative outcome study comparing the WPTA (in 
conjunction with standard drug therapy if needed) versus 
standard drug therapy alone.
A small number were recruited to this study, the first 
four available being taken. There were more who were 
unable (5, because of time constraints) or reluctant (4, 
rejected the model). The main patient objection was 
the requirement to attend weekly for 10 weeks. It needs 
to be emphasised that in the ‘real world’ of our clinic 
10  weeks of treatment is not a standard requirement. 
Many patients actually do well within their first few rou-
tine scheduled clinic appointments with clinicians taking 
a WPTA approach.
All four patients, prior to being involved in the study, 
had at some level identified stress as being important 
in causing their urticaria, which could suggest a selec-
tion bias towards patients willing to consider this type 
of intervention. Most patients recruited saw the WPTA 
as a psychotherapy/counselling-like intervention. Their 
long experience of lack of success with other measures 
may have contributed to their adherence and attendance 
at the sessions. Those patients who self-identified stress 
as an exacerbating factor may have been more likely to 
be invited (by the referring clinician), to take part and 
to complete the study, and to experience benefit from 
this type of approach. Patients do experience coincident 
flares of urticaria and emotion, of which they become 
increasingly aware during therapeutic sessions, or 
shortly afterwards. From a theoretical perspective, such 
co-occurrence (whilst keeping in mind other physical 
factors) supports the notion that emotional factors are 
important in the patient with urticaria [5, 6, 8] and that 
sometimes symptoms may be mobilised by the therapeu-
tic process. In our experience and practice, this is rarely 
a problem, but needs to be taken into account in future 
studies, and strategies put in place to manage it.
Conclusion
This study provides proof-of-concept evidence that a 
whole person approach is both feasible and acceptable 
in a biomedical clinical setting and potentially therapeu-
tically powerful for at least some patients, when used 
in tandem with standard care. The results of this study, 
while limited to a few patients, support the literature 
reporting the importance of emotional factors in CSU. A 
much larger outcome study of the whole person approach 
in direct comparison with the use of standard drug ther-
apy is warranted.
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Table 1 Urticaria Activity Scores (UAS) and  Urticaria Severity Scores (USS) before  and after  whole person treatment 
approach sessions
Patient no. and sex Disease duration at start of study UAS (maximum 42) Post-WPTA USS (maximum score 93) Post-WPTA
1. Female 23 months 20 0 37 0
2. Female 16 years 19 5 11 0
3. Female 6 years 12 4 11 0
4. Male 12 months 3 0 0 0
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